Baricitinib clinical trials
Also written LY3009104, Olumiant and INCB 028050.
How each study uses baricitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the baricitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 31 May 2018 · OLUMIANT · NDA 207924 (FDA, Drugs@FDA)
- European Union
- 13 Feb 2017 · Olumiant · EMEA/H/C/004085 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
148 studies that test it; most in 2020 (22); 1 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 10 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 4 |
| 2018 | 10 |
| 2019 | 8 |
| 2020 | 22 |
| 2021 | 10 |
| 2022 | 12 |
| 2023 | 19 |
| 2024 | 10 |
| 2025 | 5 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 59 · Other 90
Eli Lilly and Company (54) · Assistance Publique - Hôpitaux de Paris (6) · Emory University (4) · Peking University People's Hospital (4) · Peking Union Medical College Hospital (3) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (3) · Tianjin Medical University General Hospital (2) · South Valley University (2)
Often tested with
Tested in the same studies.
Tocilizumab (6) · Tofacitinib (4) · Interleukin 1 Receptor Antagonist Protein (4) · Upadacitinib (3) · Dexamethasone (3) · Adalimumab (3) · Hydroxychloroquine (3) · Remdesivir (2)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 10, 2 in phase 3
Studies that test baricitinib, phase 3 first.
- Nov 2026Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDPhase 3 · Wes Ely
- Aug 2027Safety and Efficacy of Baricitinib After Endovascular Treatment in Acute Anterior Circulation Large Vessel Occlusion: A Multicenter, Randomized Controlled Clinical TrialPhase 2/3 · The First Affiliated Hospital of University of Science and Technology of China
- Dec 2026A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersPhase 1 · AbbVie
- Dec 2026Efficacy and Safety of Baricitinib in the Post-intracerebral Hemorrhage Pulmonary InjuryPhase 1/2 · Tianjin Medical University General Hospital
- Dec 2026Baricitinib for the Lung Injury Following Spontaneous SAHPhase 2 · Tang-Du Hospital
- Mar 2027Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum DisordersPhase 1 · Tianjin Medical University General Hospital
- Jun 2027Baricitinib in the Treatment of Intestinal Behçet's SyndromePhase 2 · Peking Union Medical College Hospital
- Jul 2027ConsideRAte Study - Splenic Stimulation for RANot applicable · Galvani Bioelectronics
- Oct 2027JAK Signaling in Depression and Cognition in Male Football PlayersPhase 2 · Emory University
- Nov 2027Inflammation and Depression in People With HIVPhase 2 · Emory University
Studies
Open first, then newest update. How each study uses baricitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 149
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic DermatitisRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07262983Written as baricitinib
- Baricitinib Curative Repression of HIV-1Not yet recruitingPhase 2Emory UniversityNCT07209267Written as Baricitinib (LY3009104) 2 mg
- Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological InvolvementRecruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT06923072Written as Baricitinib
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic ArthritisRecruitingPhase 3Eli Lilly and CompanyNCT03773965Written as Baricitinib
- A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia AreataRecruitingPhase 3Eli Lilly and CompanyNCT05723198Written as Baricitinib
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and AdultsRecruitingPhase 3Eli Lilly and CompanyNCT07222137Written as Baricitinib
- A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)RecruitingPhase 3Eli Lilly and CompanyNCT07222332Written as Baricitinib
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Baricitinib
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Baricitinib
- Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment InterruptionNot yet recruitingPhase 2ANRS, Emerging Infectious DiseasesNCT07081763Written as Baricitinib 2 MG
- Precision Medicine Adaptive Network Platform Trial in Hypoxemic Acute Respiratory FailureNot yet recruitingPhase 2University of Colorado, DenverNCT07779642Written as Baricitinib
- JAK Signaling in DepressionRecruitingPhase 2Emory UniversityNCT07003997Written as Baricitinib
- A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult VolunteersRecruitingPhase 1AbbVieNCT07843693Written as Baricitinib
- Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVIDRecruitingPhase 3Wes ElyNCT06631287Written as Baricitinib
- JAK Signaling in Depression and Cognition in Male Football PlayersRecruitingPhase 2Emory UniversityNCT07608796Written as Baricitinib
- Baricitinib in the Treatment of Intestinal Behçet's SyndromeRecruitingPhase 2Peking Union Medical College HospitalNCT06849908Written as Baricitinib
- Baricitinib for Post-HSCT Persistent ThrombocytopeniaRecruitingPhase 1/2Peking University People's HospitalNCT07535645Written as Baricitinib
- Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumaticaRecruitingPhase 3University Hospital, BrestNCT07279688Written as Baricitinib 4 MG Oral Tablet
- JAK Inhibitor Dose TAPering Strategy StudyRecruitingPhase 4University Hospital, ToulouseNCT06687551Written as Baricitinib (LY3009104) 4 mg
- TPO-RA Plus Baricitinib vs. TPO-RA for ITPNot yet recruitingPhase 2Peking University People's HospitalNCT07669675Written as Baricitinib
See all 149 studies that test baricitinib →
Given beside what is tested · 5 — baricitinib is usual care or a partner of the new treatment
- Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingPhase 2Peking University People's HospitalNCT05852847Written as Baricitinib 2 MG [Olumiant]
- Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - a Pilot StudyTerminatedPhase 2Iain BressendorffNCT05897372Written as ACEi / ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorthiazide, baricitinib
- Adaptive COVID-19 Treatment Trial 2 (ACTT-2)CompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT04401579Written as Baricitinib
- Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)Status unknownPhase 3ASST Fatebenefratelli SaccoNCT04832880Written as Baricitinib Oral Tablet [Olumiant]
- A Study of Baricitinib and Simvastatin in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT01960140Written as Baricitinib
As the comparator · 2 — what is tested is compared with baricitinib
- Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose AdministrationRecruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT07554222Written as Baricitinib tablets
- Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19CompletedPhase 3Instituto de Investigación Hospital Universitario La PazNCT04890626Written as Baricitinib + dexamethasone
What changed recently
From the registry's own updates since Oct 18, 2026.
Stopped1
- Efficacy and Safety of Baricitinib in Patients With Moderate and Severe COVID-19WithdrawnNov 5, 2026NCT05056558
Codes
What other systems call baricitinib · ClinicalTrials.gg INT000188
- MeSH (NLM) C000596027baricitinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ISP4442I3YBARICITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2047232Confirmed FDA, Wikidata
- Wikidata Q4860707baricitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C127012BaricitinibOne source FDA
- DrugBank DB11817One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000596027 | baricitinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ISP4442I3Y | BARICITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2047232 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4860707 | baricitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C127012 | Baricitinib | One source FDA |
| DrugBank | DB11817 | — | One source Wikidata |
Also registered as baricitinib phosphate (UNII XIB47S8NNB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.